Pharmaceuticals news FT.com

Pfizer to halt development of closely watched weight-loss drug

US pharmaceutical group says patient in study ‘experienced potential drug-induced liver injury’

Apr 14, 2025 - 12:52
 0
Pfizer to halt development of closely watched weight-loss drug
US pharmaceutical group says patient in study ‘experienced potential drug-induced liver injury’
Read More

Tags:

Previous Article

Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): VidPrevtyn Beta, SARS...

Related Posts

Former UK IPO star Nanopore admits it is a takeover target

Former UK IPO star Nanopore admits it is a takeover target

Mar 21, 2025  0

Elliott held talks with private equity as it considered new Bayer campaign

Elliott held talks with private equity as it considered...

Mar 26, 2025  0

Merck shares sink 11% after vaccine shipments to China halted

Merck shares sink 11% after vaccine shipments to China ...

Feb 9, 2025  0